title: Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?
authors.affiliation: Oncology Department, Bristol Cancer Centre, Bristol, England.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Addeo
authors.affiliation: Department of Oncology, San Luigi Hospital, University of Turin, Turin, Italy.
authors.forename: Lucio
authors.initials: L
authors.lastname: Buffoni
authors.affiliation: Department of Oncology, Mauriziano Hospital, University of Turin, Turin, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000066491:Clinical Decision-Making; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008654:Mesothelioma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D000086002:Mesothelioma, Malignant; D018579:Patient Selection; D000068437:Pemetrexed / Q000009:adverse effects / Q000627:therapeutic use*; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D000077982:Progression-Free Survival; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D000068437:Pemetrexed